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Objectives: To compare the presence of plaques in the carotid and femoral arteries of chronic renal failure
(CRF) patients not yet on hemodialysis, or on maintenance hemodialysis, and kidney transplant patients with
those of normal controls, and to consider the relationship of plaques to serum lipoprotein(a) [Lp(a)].
Methods: There were 130 subjects divided into four groups: group 1 comprised 29 healthy controls; group 2
was made up of 33 CRF patients; group 3 of 43 hemodialysis patients; group 4 had 25 kidney transplant
recipients. All patients underwent B-mode ultrasonography examination of the right and left carotid and femoral
arteries for plaques; they were scored from 0 (no plaques) to 4 (plaques at all 4 sites). After a 14-hour over-
night fast, blood samples from all patients were evaluated for blood urea nitrogen, creatinine, and serum lipids,
including Lp(a).
Results: A plaque score of zero was most common in group 1 (93%), followed by groups 4 (68%), 3 (51.2%),
and 2 (39.4%). Plaque scores of 1–2 increased from group 1 (6.8%) through groups 2 (24.3%) and 3 (25.6%)
to group 4 (32%). Plaque scores of 3–4 were lowest in groups 1 and 4 (0%) and highest in group 2 (36.4%);
they were 23.3% in group 3. Serum Lp(a) in groups 1, 2, 3, and 4 were 42, 56, 55, and 54 mg/dL, respectively.
There were significant differences in plaque scores (p < 0.001) and serum Lp(a) (p = 0.016) among the four
groups. A significant positive correlation was found between plaque score and patient age in groups 2, 3, and
4. There was a significant correlation between plaque score and serum Lp(a) in group 3.
Conclusion: Age is an important factor in the occurrence of arterial plaques in renal failure patients, before
dialysis and on maintenance hemodialysis, and in kidney transplant patients. The positive association between
serum Lp(a) and arterial plaques in hemodialysis patients may indicate that Lp(a) is a factor in the rapidly
progressive atherosclerosis seen in hemodialysis patients. [Hong Kong J Nephrol 2004;6(2):109–11]
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INTRODUCTION
Patients with chronic renal failure (CRF), end-stage re-
nal disease under hemodialysis, and kidney transplant
suffer from excess mortality due to atherosclerotic car-
diovascular disease frequently attributed to a process
of accelerated atherosclerosis [1,2].
Lipoprotein(a) [Lp(a)], when present in high levels
in plasma, is recognized as an independent risk factor
for premature atherosclerotic coronary heart disease.
Renal failure studies reveal an increase in the plasma
concentration of Lp(a). Increased Lp(a) levels could
be a contributing factor in the increased incidence of
atherosclerotic disease observed in CRF, hemodialysis,
and kidney transplant patients [3–5]. The need for early
detection of atherosclerotic lesions in these patients
has led to growing interest in using ultrasonography to
study areas such as the carotid and femoral arteries for
plaques [6].
In this cross-sectional study, we compared the
presence of discrete plaques in the carotid and femoral
arteries of a group of CRF patients not yet on hemo-
dialysis or on maintenance hemodialysis and kidney
transplant patients with those of normal controls. We
considered the relationship of plaques to serum Lp(a)
in these patients.
METHODS
Of 130 subjects enrolled in the study, 29 were healthy
controls (group 1: 15 women, 14 men), 33 were CRF
patients not yet on dialysis (group 2: 18 women, 15
men), 43 were hemodialysis patients (group 3: 19
women, 24 men), and 25 were kidney transplant re-
cipients (group 4: 16 women, 9 men). Exclusion cri-
teria were cigarette smoking, body mass index more
than 25, taking anti-lipid medication, diabetes melli-
tus, recent myocardial infarction, vascular disease, and
active or chronic infection.
All patients underwent B-mode ultrasonography
using a Honda HS-2000 Ultrasound System (Honda
Electronics Co Ltd, Aichi, Japan) with a 7.5 MHz linear
probe. The right and left carotid and femoral arteries
were scanned for plaques. Patients were scored from 0
(no plaques) to 4 (plaques at all 4 sites).
Blood urea nitrogen, creatinine, and serum lipids,
consisting of serum Lp(a), triglyceride, total cholesterol,
high-density lipoprotein cholesterol (HDL-C), and low-
density lipoprotein cholesterol (LDL-C), were eval-
uated after a 14-hour overnight fast. Blood samples
were obtained from the antecubital vein in groups 1,
2, and 4. For hemodialysis patients (group 3), blood
samples were obtained from the venous line at the be-
ginning of hemodialysis. Serum LDL-C was calculat-
ed using the Friedewald formula, and creatinine clear-
ance was evaluated from serum creatinine, age, and
body weight.
RESULTS
The mean age of group 1 was 45 ± 10.4 years, of group
2 was 62 ± 14.5 years, of group 3 was 47 ± 16.4 years,
and of group 4 was 42.8 ± 12.4 years. The known
duration of CRF in group 2 was 39 ± 18 months. In
group 3, the mean length of time patients had been on
hemodialysis was 44 ± 31 months. In group 4, patients
had received a kidney transplant a mean of 63 ± 36
months prior to the study. Group 1 had normal creat-
inine clearance (95–105 mL/minute). In group 3, a
creatinine clearance of less than 10 mL/minute was ob-
served. Groups 2 and 4 had mean creatinine clear-
ances of 30.6 ± 18 mL/minute and 50 ± 8.6 mL/minute,
respectively.
A plaque score of zero was most common in group
1 (93%), followed by groups 4 (68%), 3 (51.2%), and
2 (39.4%). The incidence of plaque scores of 1–2 in-
creased from group 1 (6.8%) through groups 2 (24.3%)
and 3 (25.6%) to group 4 (32%). The incidence of plaque
scores of 3–4 was lowest in groups 1 and 4 (0%) and
highest in group 2 (36.4%); it was 23.3% in group 3.
Serum Lp(a) concentrations in groups 1, 2, 3, and 4
were 42 ± 20, 56 ± 23, 55 ± 16, and 54 ± 20 mg/dL,
respectively.
There was a significant difference in plaque scores
among the four groups (p < 0.001), between groups
1 and 2 (p < 0.001), and between groups 1 and 3 (p =
0.005). There was a marginal difference in plaque
score between groups 1 and 4 (p = 0.052). Analysis of
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variance showed a significant difference in serum Lp(a)
concentration among the four groups (p = 0.016), be-
tween groups 1 and 2 (p = 0.041), and between groups
1 and 3 (p = 0.05).
A significant positive correlation was found between
plaque score and patient age in group 2 (p = 0.002),
group 3 (p < 0.001), and group 4 (p = 0.001). No sig-
nificant correlations were found between plaque score
and total cholesterol, HDL-C, LDL-C, triglyceride,
Lp(a), and the gender of subjects in groups 1, 2, and 4.
There was a significant correlation between plaque
score and serum Lp(a) in group 3 (partial corre-
lation test after adjustment for LDL-C, cholesterol,
age, and creatinine clearance, r = 0.388, p = 0.011).
No significant correlation was observed in group 3
between plaque score and total cholesterol, HDL-C,
LDL-C, triglyceride, and gender.
DISCUSSION
This study showed that age is an important factor in
the occurrence of arterial plaques in renal failure
patients, before dialysis and on maintenance hemo-
dialysis, and in kidney transplant patients. There was a
positive association between serum Lp(a) and arterial
plaques in hemodialysis patients, showing that Lp(a)
could be a factor in the rapidly progressive athero-
sclerosis seen in hemodialysis patients. The extra-
ordinarily high mortality in end-stage renal disease pa-
tients on hemodialysis due to cardiovascular disease
[7] has led to interest in non-traditional atherosclerotic
cardiovascular disease risk factors that are prevalent in
end-stage renal disease, such as Lp(a). This needs more
attention because of its effect on the acceleration of
the rapidly progressive atherosclerosis in hemodialysis
patients [8,9].
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